Related references
Note: Only part of the references are listed.A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis
Aimee M. Crago et al.
ANNALS OF SURGERY (2013)
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)
D. Garbay et al.
ANNALS OF ONCOLOGY (2012)
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors
L. Schirosi et al.
ANNALS OF ONCOLOGY (2012)
The treatment of desmoid tumors: a stepwise clinical approach
S. Bonvalot et al.
ANNALS OF ONCOLOGY (2012)
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples
Audrey Didelot et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2012)
Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Margaret von Mehren et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
N. Penel et al.
ANNALS OF ONCOLOGY (2011)
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
Mrinal M. Gounder et al.
CLINICAL CANCER RESEARCH (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation
Sebastien Salas et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population
Florian Grabellus et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
MIQE precis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments
Stephen A. Bustin et al.
BMC MOLECULAR BIOLOGY (2010)
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
A. Dufresne et al.
BRITISH JOURNAL OF CANCER (2010)
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Rashmi Chugh et al.
CLINICAL CANCER RESEARCH (2010)
Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
Vassiliki Kotoula et al.
PLOS ONE (2009)
Desmoid-type fibromatoses involving the brachial plexus:: treatment options and assessment of c-KIT mutational status
J Seinfeld et al.
JOURNAL OF NEUROSURGERY (2006)
Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis
Anthony Goncalves et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians
S Krüger et al.
LEUKEMIA (2006)
Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis
M Gega et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
A Hansmann et al.
CANCER (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia - potential clinical significance
K Inokuchi et al.
LEUKEMIA (2002)
Share Paper
